# EDGAR Filing Document

**Accession Number:** 0001422142
**File Stem:** 0001193125-26-104333
**Filing Date:** 2026-3
**Character Count:** 20920
**Document Hash:** d32f751a7ee00a5e07fea2524b152924
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-104333.hdr.sgml**: 20260312

**ACCESSION NUMBER**: 0001193125-26-104333

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260312

**DATE AS OF CHANGE**: 20260312

**EFFECTIVENESS DATE**: 20260312

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Whitehawk Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001422142
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 611547850
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294256
- **FILM NUMBER:** 26748595

**BUSINESS ADDRESS:**
- **STREET 1:** 2 HEADQUARTERS PLAZA
- **STREET 2:** EAST BUILDING, 11TH FLOOR
- **CITY:** MORRISTOWN
- **STATE:** NJ
- **ZIP:** 07960
- **BUSINESS PHONE:** 551-321-2234

**MAIL ADDRESS:**
- **STREET 1:** 2 HEADQUARTERS PLAZA
- **STREET 2:** EAST BUILDING, 11TH FLOOR
- **CITY:** MORRISTOWN
- **STATE:** NJ
- **ZIP:** 07960

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aadi Bioscience, Inc.
- **DATE OF NAME CHANGE:** 20210826

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aerpio Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20170316

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ZETA ACQUISITION CORP II
- **DATE OF NAME CHANGE:** 20071227

**As filed with the Securities and Exchange Commission on March 12, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***Under***

***The Securities Act of 1933***

## WHITEHAWK THERAPEUTICS, INC.
**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **61-1547850** |
| **(State or other jurisdiction of** | **(I.R.S. Employer** |
| **incorporation or organization)** | **Identification No.)** |

---

**2 Headquarters Plaza** 

**East Building, 11th Floor** 

**Morristown, NJ 07960** 

**(Address of Principal Executive Offices, including zip code)** 

**Amended and Restated 2021 Equity Incentive Plan** 

**2021 Employee Stock Purchase Plan** 

**(Full title of the plan)** 

**David J. Lennon** 

**Chief Executive Officer** 

**2 Headquarters Plaza** 

**East Building, 11th Floor** 

**Morristown, NJ 07960** 

**(551) 321-2234** 

**(Name, address and telephone number, including area code, of agent for service)** 

***Copies to:***

**Dan Koeppen, Esq.** 

**Robert L. Wernli, Jr., Esq.** 

**Wilson Sonsini Goodrich & Rosati, P.C.** 

**12235 El Camino Real** 

**San Diego, California 92130** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

This Registration Statement on Form S-8 (the "**Registration Statement**") is filed by Whitehawk Therapeutics, Inc. (the "**Registrant**") for the purpose of registering (i) an additional 2,357,285 shares of common stock of the Registrant reserved for issuance pursuant to future awards under the Registrant's Amended and Restated 2021 Equity Incentive Plan (the "**2021 Plan**") as a result of the annual evergreen increase under the 2021 Plan and (ii) an additional 471,457 shares of common stock of the Registrant reserved for issuance under the 2021 Employee Stock Purchase Plan (the "**2021 ESPP**") as a result of the annual evergreen increase under the 2021 ESPP.

Accordingly, contents of (i) the previous Registration Statement on Form S-8 filed by the Registrant with the Securities and Exchange Commission (the "**Commission**") on September 24, 2021 ([File No. 333-259787](http://www.sec.gov/Archives/edgar/data/1422142/000119312521282449/d235283ds8.htm)) (the "**2021 Form S-8**"), (ii) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on March 17, 2022 ([File No. 333-263639](http://www.sec.gov/Archives/edgar/data/1422142/000119312522078324/d288021ds8.htm)) (the "**2022 Form S-8**"), (iii) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on March 29, 2023 ([File No. 333-270933](http://www.sec.gov/Archives/edgar/data/1422142/000119312523083652/d464068ds8.htm)) (the "**2023 Form S-8**"), (iv) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on February 12, 2024 ([File No. 333-277020](http://www.sec.gov/Archives/edgar/data/1422142/000119312524032285/d772211ds8.htm)) (the "**2024 Form S-8**") and (v) the previous Registration Statement on Form S-8 filed by the Registrant with the Commission on March 28, 2025 ([File No. 333-286229](http://www.sec.gov/Archives/edgar/data/1422142/000119312525067200/d906446ds8.htm)) (the "**2025 Form S-8**", and together with the 2021 Form S-8, 2022 Form S-8, 2023 Form S-8 and 2024 Form S-8, the "**Previous Forms S-8**"), including the information incorporated by reference therein and the periodic reports filed after the Previous Forms S-8 to maintain current information about the Registrant, are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

**PART I** 

**INFORMATION REQUIRED IN THE PROSPECTUS** 

The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the equity benefit plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

The Registrant hereby incorporates by reference into this Registration Statement the following documents previously filed with the Securities and Exchange Commission (the "**SEC**"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) The Registrant's Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1422142/000119312526104158/whwk-20251231.htm) <u> </u> for the fiscal year ended December 31, 2025, filed with the SEC on March 12, 2026 (the "**Annual Report** ").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) All other reports filed with the SEC pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of
1934, as amended (the "**Exchange Act** "), since the end of the fiscal year covered by the Annual Report (other than the portions of these documents not deemed to be filed).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) The description of the Registrant's capital stock contained in [Exhibit 4.1](http://www.sec.gov/Archives/edgar/data/1422142/000162828025015269/exh41-descriptionofsecurit.htm) to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 28, 2025, including any amendment or report filed for the purpose
of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement that indicates that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; *provided*, *however*, that documents or information deemed to have been furnished and not filed in accordance with the rules of the SEC shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

**Item 8. Exhibits.** 

The Registrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

**EXHIBIT INDEX** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit<br>Number** | <br>**Exhibit Description** | <br>**Filed<br>Herewith** | **Form** | **File No.** | **Exhibit** | **Filing Date** |
| 4.1 | [Amended and Restated Whitehawk Therapeutics, Inc. 2021 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1422142/000162828025015269/exh105-2021equityincentive.htm) |  | 10-K | 001-38560 | 10.5 | March 28, 2025 |
| 4.2 | [Form of Stock Option Agreement under the Whitehawk Therapeutics, Inc. 2021 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1422142/000162828025015269/exh106-formstockoptionagre.htm) |  | 10-K | 001-38560 | 10.6 | March 28, 2025 |
| 4.3 | [Form of Restricted Stock Unit Award Agreement under the Whitehawk Therapeutics, Inc. 2021 Equity Incentive Plan](http://www.sec.gov/Archives/edgar/data/1422142/000162828025015269/exh1013-formofrsuagreement.htm) |  | 10-K | 001-38560 | 10.13 | March 28, 2025 |
| 4.4 | [Amended and Restated Whitehawk Therapeutics, Inc. 2021 Employee Stock Purchase Plan](http://www.sec.gov/Archives/edgar/data/1422142/000162828025015269/exh107-employeestockpurcha.htm) |  | 10-K | 001-38560 | 10.7 | March 28, 2025 |
| 5.1 | [Opinion of Wilson Sonsini Goodrich & Rosati, P.C.](d82551dex51.htm) | X |  |  |  |  |
| 23.1 | [Consent of Independent Registered Public Accounting Firm, BDO USA, P.C.](d82551dex231.htm) | X |  |  |  |  |
| 23.3 | [Consent of Wilson Sonsini Goodrich & Rosati, P.C. (included in Exhibit 5.1 hereto)](d82551dex51.htm) | X |  |  |  |  |
| 24.1 | [Power of Attorney (included on the signature page hereto)](#sig) | X |  |  |  |  |
| 107.1 | [Filing Fee Table](d82551dexfilingfees.htm) | X |  |  |  |  |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Morristown, State of New Jersey, on March 12, 2026.

---

| | |
|:---|:---|
| **WHITEHAWK THERAPEUTICS, INC.** | **WHITEHAWK THERAPEUTICS, INC.** |
| By: | /s/ David J. Lennon |
|  | David J. Lennon |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints David J. Lennon and Scott Giacobello, and each of them, as his or her true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments) on Form S-8, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact, proxy, and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact, proxy and agent, or any substitute of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ David J. Lennon | President, Chief Executive Officer and Director | March 12, 2026 |
| David J. Lennon | (Principal Executive Officer) |  |
| /s/ Scott Giacobello | Chief Financial Officer | March 12, 2026 |
| Scott Giacobello | (Principal Financial and Accounting Officer) |  |
| /s/ Caley Castelein | Chairman | March 12, 2026 |
| Caley Castelein |  |  |
| /s/ Neil Desai | Director | March 12, 2026 |
| Neil Desai |  |  |
| /s/ Behzad Aghazadeh | Director | March 12, 2026 |
| Behzad Aghazadeh |  |  |
| /s/ Anupam Dalal | Director | March 12, 2026 |
| Anupam Dalal |  |  |
| /s/ Richard Maroun | Director | March 12, 2026 |
| Richard Maroun |  |  |
| /s/ Emma Reeve | Director | March 12, 2026 |
| Emma Reeve |  |  |
| /s/ Mohammed Hirmand | Director | March 12, 2026 |
| Mohammed Hirmand |  |  |
| /s/ Baiteng Zhao | Chairman | March 12, 2026 |
| Baiteng Zhao |  |  |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g82551dsp6.jpg) | Wilson Sonsini Goodrich & Rosati<br>Professional Corporation<br>12235 El Camino Real<br>San Diego, California 92130-3002<br>o: 858.350.2300<br>f: 866.974.7329 |

---

March 12, 2026

Whitehawk Therapeutics, Inc.

2 Headquarters Plaza

East Building, 11th Floor

Morristown, NJ 07960

---

| | |
|:---|:---|
| **Re:** | **<u>Registration Statement on Form S-8</u>**  |

---

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed by Whitehawk Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), with the Securities and Exchange Commission on or about the date hereof, in connection with the registration under the Securities Act of 1933, as amended, of an aggregate of 2,828,742 shares (the "<u>Shares</u>") of the Company's common stock, par value $0.0001 per share ("<u>Common Stock</u>"), consisting of (i) an additional 2,357,285 shares of Common Stock reserved for issuance pursuant to future awards under the Company's Amended and Restated 2021 Equity Incentive Plan (the "<u>2021 Plan</u>") as a result of the annual evergreen increase under the 2021 Plan and (ii) an additional 471,457 shares of Common Stock reserved for issuance under the 2021 Employee Stock Purchase Plan (the "<u>2021 ESPP</u>") as a result of the annual evergreen increase under the 2021 ESPP. As the Company's legal counsel, we have reviewed the actions proposed to be taken by the Company in connection with the issuance and sale of the Shares to be issued under such plans (which plans are referred to herein as the "<u>Plans</u>").

It is our opinion that the Shares, when issued and sold in the manner referred to in the Plans and pursuant to the agreements that accompany the Plans, will be legally and validly issued, fully paid and nonassessable.

We consent to the use of this opinion as an exhibit to the Registration Statement, and further consent to the use of our name wherever appearing in the Registration Statement and any amendments thereto.

---

| |
|:---|
| Very truly yours, |
| /s/ WILSON SONSINI GOODRICH & ROSATI |
| WILSON SONSINI GOODRICH & ROSATI, |
| Professional Corporation |

---

AUSTIN BEIJING BOSTON BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE

## Exhibit 23.1

**Exhibit 23.1** 

<u>Consent of Independent Registered Public Accounting Firm</u> 

We hereby consent to the incorporation by reference in this Registration Statement of our report dated March 12, 2026, relating to the financial statements of Whitehawk Therapeutics, Inc (the "Company") appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

/s/ BDO USA, PC

San Diego, California

March 12, 2026

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

#### Exhibit 107

#### Calculation of Filing Fee Tables

#### Form S-8
(Form Type)

#### Whitehawk Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

#### Table 1 – Newly Registered Securities

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**Security Type** | **Security<br>Class<br>Title** | **Fee<br>Calculation<br>Rule** | **Amount<br>Registered<sup>(1)</sup>** | **Maximum**<br>**Aggregate**<br>**Offering**<br>**Price** | **Fee**<br>**Rate** | **Amount of<br>Registration<br>Fee** |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock,<br>par value<br>$0.0001 per<br>share, reserved<br>for issuance<br>under the<br>Registrant's<br>Amended and<br>Restated 2021<br>Equity Incentive<br>Plan | Rule<br>457(c)<br>and Rule<br>457(h) | 2357285<sup>(2)</sup>$3.94<sup>(4)</sup> | $9287702.90 | $0.00013810 | $1282.64 |
| &nbsp;&nbsp;&nbsp;Equity | Common Stock,<br>par value<br>$0.0001 per<br>share, reserved<br>for issuance<br>under the<br>Registrant's 2021<br>Employee Stock<br>Purchase Plan | Rule<br>457(c)<br>and Rule<br>457(h) | 471457<sup>(3)</sup>$3.35<sup>(5)</sup> | $1579380.95 | $0.00013810 | $218.12 |
| &nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;**Total Offering Amounts** | &nbsp;&nbsp;&nbsp;**Total Offering Amounts** | 2828742 | $10867083.85 |  | $1500.76 |
| &nbsp;&nbsp;&nbsp;**Total Fee Offsets<sup>(6)</sup>** | &nbsp;&nbsp;&nbsp;**Total Fee Offsets<sup>(6)</sup>** | &nbsp;&nbsp;&nbsp;**Total Fee Offsets<sup>(6)</sup>** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;**Net Fee Due** | &nbsp;&nbsp;&nbsp;**Net Fee Due** |  |  |  | $1500.76 |

---

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "**Securities Act** "), this registration statement (the "**Registration Statement**") shall also cover any additional shares of the Registrant's common stock, par value $0.0001 per share ()"**Common Stock**") that become issuable under the Registrant's Amended and Restated 2021 Equity Incentive Plan (the "**2021 Plan**") or the Registrant's 2021 Employee Stock Purchase Plan (the "**2021 ESPP**") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without receipt of consideration or conversion of the Registrant's Common Stock that increases the number of outstanding shares of Common Stock.

(2) Represents an automatic increase of 2,357,285 shares of Common Stock reserved for issuance pursuant to future awards under the 2021 Plan as a result of the annual evergreen increase under the 2021 Plan.

(3) Represents an automatic increase of 471,457 shares of Common Stock reserved for issuance pursuant to the 2021 ESPP as a result of the annual evergreen increase under the 2021 ESPP.

(4) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $3.94, which is the average of the high and low prices of shares of Common Stock on The Nasdaq Capital Market ()"**Nasdaq**") on March 9, 2026 (such date being within five business days of the date that this Registration Statement was filed with the U.S. Securities and Exchange Commission (the "**SEC** ")).

(5) Pursuant to Rule 457(c) and 457(h) under the Securities Act, and solely for the purpose of calculating the registration fee, the proposed maximum offering price per share is $3.35, which is 85% of the average of the high and low prices of shares of Common Stock on Nasdaq on March 9, 2026 (such date being within five business days of the date that this Registration Statement was filed with the SEC). Pursuant to the 2021 ESPP, the purchase price of the shares of common stock reserved for issuance thereunder will be 85% of the lower of the fair market value of the common stock on (i) the first trading day of the offering period or (ii) the exercise date.

(6) The Registrant does not have any fee offsets.